Aim: To assess the validity of the translated Spanish Cancer Symptom Scale.
| INTRODUCTION
Approximately 62 000 patients were living with cancer in 2010 in Puerto Rico (Centeno-Girona et al., 2013) . While localized treatments such as radiation and surgery have led to higher cure rates (AbdelWahab et al., 2012) , they often produce disruptive side effects and symptoms that have negative impacts on health-related quality of life (HRQOL) (Gonzalez-Mercado, Williams, P. D., Williams A. R., Pedro, & Colon, 2017; Tofthagen & McMillan, 2010) . Further, these symptoms are associated with disability and health care overuse and are therefore a source of considerable economic burden (Carlotto, Hogsett, Maiorini, Razulis, & Sonis, 2013) . As a significant number of Hispanics, including Puerto Ricans, immigrate to international territories due to personal and economic reasons (US Department of Commerce, US Census Bureau, Population Division, 2010), taking their cancer risk with them, there is a crucial need for valid and reliable Spanish scales to assess the symptom experience in the Spanish-speaking population.
Despite the variation in symptom reporting that may exist among ethnic groups, it is well documented that Hispanics, including Puerto Ricans, are an understudied population who are underrepresented in clinical trials, especially in symptom research (Canino et al., 2008; Puerto Rico Cancer Control Coalition, 2015) . Recent studies suggest that lack of culturally appropriate and language-specific tools may contribute to, or explain, Hispanics' limited participation in research (Galvao, 2011; Jerome-D'Emilia, Suplee, & Akincigil, 2015; Li, McCardel, ClarK, Kinsella, & Berch, 2001) . Notably, Spanish validated instruments provide an opportunity to uniformly assess and investigate the symptom burden of Spanish-speaking patients (Sanchez et al., 2016) . In addition, incorporating these instruments into practice may help nurses and clinicians to ameliorate some difficulties experienced by patients during the treatment phase, promote self-care and symptom management strategies, dose adjustment or change of therapies, and complement evidence-based practice (Sanchez et al., 2016; Trujillo et al., 2016) .
Research on the symptom experience of Hispanics Puerto Rican patients during cancer treatment have most often focused on symptom severity. One study using the Spanish MD Anderson Symptom Inventory (MDASI) showed that fatigue (44.7%), disturbed sleep (42.1%), dry mouth (42.1%), difficulty remembering (36.8%), numbness/tingling (36.8%), and pain (34.2%) are highly prevalent severe symptoms among Hispanic Puerto Rican prostate cancer patients on neoadjuvant hormonal therapy . In addition, the participants of that study reported that their severity of the symptom experience affected their general activity and mood.
Similar findings were also found by Gonzalez, Williams P. D., Tirado, and Williams, A. R. (2011) in their preliminary study of Puerto Rican cancer patients using the Spanish Therapy-Related Symptoms Checklist, in which patients reported severe fatigue/feeling sluggish (56%), difficulty sleeping (54%) and depression (46%), and that the Spanish Therapy-Related Symptoms Checklist scores correlated negatively with HRQOL (r = −0.37; P < .01). In another study, one notable finding was that health care providers under-recognized and under-treated cancer-related-symptoms, especially among the Hispanic population (Yoon et al., 2008) .
The knowledge base of cancer therapy-related symptoms in Hispanic patients is increasing, yet there have been limited scales that were specifically designed to assess the total symptom experience in patients to date (McMillan, Tofthagen, Choe, & Rheingans, 2015) .
Therefore, much interest has emerged in developing instruments that measure the presence, intensity, distress, frequency, and interference of a list of symptoms such as the Cancer Symptom Scale (CSS).
The CSS was developed based on a review of literature and of existing symptom scales (Cleeland, 2014; McMillan et al., 2015; Portenoy et al., 1994) . Literature findings supported the development of a scale to assess multiple dimensions of symptoms experienced by persons with cancer. Consequently, the CSS was developed to facilitate the assessment of 35 symptoms beyond the dimension of intensity, allowing for better understanding of the impact of a given symptom, and to prioritize the symptoms causing patients the most distress, or interference at the greatest frequency. However, because the CSS was developed and validated only in English (McMillan et al., 2015) , the validation of the tool in Spanish was considered to be critical. Thus, the proposed study provides a unique opportunity to fill this knowledge gap in symptoms science, as well as advance the nursing field, by estimating the psychometric validity of the Spanish-translated CSS in a sample of Puerto Rican patients. A valid Spanish CSS will comprehensively assess symptoms and hastened development of individualized symptom management interventions.
| METHODS

| Aim
This study aimed to develop a Spanish version of the CSS through the translation of the new CSS from English into Spanish. Additionally, the purpose of this study was to assess the validity of the translated Spanish-CSS.
| Methodology
| Study design
This study used a descriptive, cross-sectional design to study the validity and reliability of the newly translated CSS.
| Translation process
The development of the Spanish version of the CSS was conducted using a double translation and back-translation processes. Specifically, the CSS was translated into Spanish by the principal investigator (PI), who is a native Puerto Rican advanced practice nurse. The initial Spanish version was then back-translated into English by a different/second bilingual/native Puerto Rican nurse practitioner. The two nurses then met to modify, discuss, and accept the final version of the instrument. The final version maintained the design and structure of the original instrument. Once the final version was accepted by both authors, the validation process started. 
| Instruments
The following self-report instruments were completed by study partic- 
| Cancer Symptom Scale
The CSS measures the presence, intensity, distress, frequency, and interference of a list of 35 symptoms (McMillan et al., 2015) . The presence of symptoms was defined as a yes or no on each item. For each symptom, patients are asked four questions that describe their experience (intensity, distress, frequency, and interference) during the past week. A typical question for the CSS is: "You had 'Fatigue; no energy' this week? and How severe or intense Fatigue; no energy has been;" Intensity/severity was rated on numeric 1 to 10 scales from "least" to "most," (0 was not used because failing to endorse the symptom was considered to be equivalent to a zero score) and distress, frequency, and interference on numeric 0 to 10 scales from Correlations ranged from r = −0.34 to −0.56; P < .001 (at the hypothesized levels), thus, supporting construct validity. In addition, test-retest reliability coefficients for the English version of the CSS subscales ranged from r = 0.74 to 0.81 in a subset of 15 patients, and Cronbach's alphas above .70 were reported (N = 234) (McMillan et al., 2015) .
| MD Anderson Symptom Inventory
The Spanish version of the MDASI was used to validate the construct validity of the CSS. The MDASI contains 13 items measuring cancer patient's severity of multiple common symptoms across all cancer types. For each item, patients are asked to indicate how severe the symptoms have been in the past 24 hours. A typical item for the MDASI is: "Your pain at its worst." It was rated on numeric rating (0 to 10) scales from "not present" to "as bad as you can imagine." Scores of the MDASI can range between 0 and 130. High scores mean higher severity of symptoms.
The MDASI has been tested for reliability and validity with cancer survivors (Cleeland, 2014) . The initial MDASI psychometric properties were evaluated in three samples of patients with various cancer types at the MD Anderson Cancer Center in Texas (Cleeland et al., 2000) . Researchers found that the 13 items MDASI explained approximately 64% of the variability in symptom interference. With respect to construct validity, findings from the principal axis factor analysis showed that the factor loadings of these 13 core items were distributed across two factors or constructs. The gastrointestinal symptoms of nausea, vomiting, and lack of appetite appeared to load on to the same construct, and the remaining items loaded into a more general symptoms construct. Further, the known-group validity of the MDASI was evaluated by assessing the instrument's ability to distinguish between two groups from the validation sample that are known to be different according to the ECOG performance status (good n = 143 or poor n = 184). Indeed, researchers found significant differences in mean symptom severity scores (2.36 vs. 3.62; P < 0.001) and mean symptom interference scores (2.95 vs. 5.31; P < 0.001) between participants with good performance status compared with those with a poor performance status.
Cronbach alphas above 0.80 for the 13 symptoms core items and for the interference items were obtained in both, the validation and the cross-validation sample. In the present study, the MDASI (Spanish) internal consistency reliability was 0.69.
| The Functional Assessment of Cancer Therapy-General questionnaire
The FACT-G questionnaire was developed by Cella and colleagues specifically to assess QOL in cancer survivors (Cella et al., 1993) . The FACT-G version 4 includes 27 statements about five domains of QOL (eg, "I have lack of energy," "I have accepted my illness"), which were rated by the patients who were asked to indicate the degree to which they felt that each statement was true during the preceding week. Each item is anchored by a five-point Likert-type scale response Cronbach's alpha was 0.89 (Cella et al., 1998) .
| Demographic data and health form
Demographics included the respondent's age, gender, ethnicity, and years of education. Information on diagnosis and treatment modality was also obtained. The research assistant obtained that information from the participants' self-report on the demographic form.
| Data collection
Prior to beginning data collection, approval by the Human Subjects Committee was granted. The PI, who is a native Puerto Rican advanced practice nurse, visited the oncology ambulatory clinics to screen potential participants. Participants were included if they had a diagnosis of cancer, had received at least two or more rounds of therapy, and were at least 21 years of age or older. Data collection was conducted in June 2016.
Eligible participants were formally asked if they wanted to participate in the study. They were given an information sheet and signed informed consent after they indicated their understanding of the study procedures and willingness to participate. All patients interviewed by the PI were assured that their decision to participate would not affect their care in any way. Responses were then recorded on the study instruments. Finally, a subgroup of 15 patients agreed to complete the CSS a second time after a short delay of 1 to 2 hours.
| Data analysis
Descriptive statistics were calculated on demographics and disease characteristics of the sample. In addition, descriptive statistics were conducted on the prevalence of severity, distress, frequency, and interference with the participants' life of the occurrence of each symptom. The construct validity of the CSS was evaluated through comparison with items of a tool that measures the same symptom severity construct. Thus, to investigate the construct validity of the Spanish CSS, we computed the Spearman correlation coefficients between the matched Intensity Items of the CSS and the MDASI.
Further, validity was evaluated in a subgroup of participants by computing the Spearman correlations coefficients between CSS subscale total scores and a measure of QOL, a related concept. We expected moderate to strong negative correlations between CSS subscale total scores and the FACT-G total scores. In order to evaluate discriminant validity, whether participants receiving treatments would be more likely to report more severe symptoms than a subgroup of patients of the post/treatment/survivorship clinics, an independent samples t-test for the intensity items of the CSS was computed. The test-retest reliability of the Spanish CSS was evaluated by administering the questionnaire with a brief delay and computing the Spearman correlations between test and re-test CSS subscale total scores.
Spearman's rho is a more conservative estimate when small samples are used. Internal consistency for the subscales scores was measured using Cronbach's alpha. 3 | RESULTS
| Sample characteristics
The demographic and disease characteristics of the 121 patients are illustrated in Table 1 . The participants' average age was 61.6 years (SD = 12.0; range 30 to 91). More than half of the participants were female (58.7%) and White-Hispanics (92%). The participants were, for the most part, well-educated with an average of 12.4 years of education (SD = 4.5). 
| Validity via correlations
All the intensity items of the Spanish MDASI correlated significantly with the matched items on the Spanish CSS (rho .55-.82, P < .002) (Table 3 ). In a subgroup of 77 participants that responded to both scales (CSS and FACT-G), CSS subscale total scores correlated significantly with the total scores from the QOL scale, the FACT-G (Table 4 ).
All correlations were moderate (rho −.61 to −.65, P < .001) as expected. With respect to discriminant validity (Table 5) , participants receiving chemotherapy treatment (n = 51) tended to experience significantly worse hair loss, taste change, poor appetite, and worry than those participants from the post/treatment/survivorship clinic (n = 32) (z = −1.9-2.2, P < .05). However, participants receiving chemotherapy treatment did not differ significantly on the remaining intensity items than those participants from the post/treatment/survivorship clinic.
| Reliability of the CSS
Results of the test-retest reliability of the Spanish CSS showed adequate stability over time of all four of the scales, with the frequency subscale having the highest estimate of reliability (rho.74, P < .001) ( Table 6 ). In the Puerto Rican sample, the Spanish CSS internal consistency reliability was 0.98.
| DISCUSSION
As new cancer therapies are being developed, and with them new side effects and behavioural symptoms being reported, it is particularly important to have available useful, reliable, and valid Spanish translated instruments that can be widely used in clinical practice and research (Sanchez et al., 2016; Trujillo et al., 2016) . Overall, the items of the CSS contain four key aspects/domains (ie, severity, distress, frequency, and interference with daily life) of the symptom experience that cancer patients need to cope with during their disease trajectory. In the current study, we reported on the psychometric validity of a Spanish-translated CSS in a sample of Puerto Rican patients. Our findings suggest that the Spanish CSS has good validity 
and reliability for determining the symptom profile of Puerto Rican cancer patients during treatments, who participated in this study.
Findings of the current study have potential international relevance. Although not studied in other Spanish-speaking populations, it is possible that this scale might be usable in them. While there are some differences in how the language is spoken among Spanish speaking countries, the words in this scale are generally those that would have a direct translation from English into Spanish, and thus, it is likely that the Spanish version may be widely useful around the world. However, further research is needed to confirm this.
Symptom research contributes to the exploration of the complexities associated with cancer therapy and symptom management. In the original study using the English version of the CSS, fatigue, pain, dry mouth, change in taste, and numbness/tingling feet were reported as the symptoms with higher prevalence (McMillan et al., 2015) . Interestingly, although Hispanic Puerto Ricans in the current study also However, when combined with the fact that participants in the current study all had mean intensity and frequency scores greater than the midpoint of the scale, and that 22 symptoms had mean distress and intensity scores equal or greater than the midpoint of the scale, it does highlight the importance of conducting a routine assessment of symptoms during the cancer trajectory. Nevertheless, it is an important concern for nurses that not only severe and distressing symptoms may be exacerbated during treatments and interference with daily life but may also lead to a need for dose adjustment or interruption of treatments, non-compliance, and/or abandonment of treatment, and thus decreased survival if left untreated (Aguado Loi et al., 2013; Cleeland, 2007; Gunn et al., 2013; Hanna et al., 2015) .
| Validity
As expected, we observed that the intensity items of the Spanish CSS Additional evidence of validity was provided by the differences found in patients who were currently undergoing treatment compared with cancer survivors who had completed treatment. Participants receiving chemotherapy treatment perceived significantly greater severity of some symptoms (eg, hair loss) than those participants from the post/treatment/survivorship clinic, which demonstrates the good discrimination ability of these items on the instrument. Unexpectedly, the differences with the other 27 intensity symptoms (eg, fatigue)
were not significant. The lack of significant difference may suggest that the subgroup of participants from the post/treatment/survivorship clinic may continue to have persistent severe symptoms after completion of treatment; further study of this issue is needed. Nonetheless, this suggests that there may be a greater need to extend symptom surveillance, treatment, and control beyond treatment, in order to enhance the health and functioning of our patients (Cleeland et al., 2013) . Further, longitudinal studies with a larger sample should examine the trajectory of cancer and cancer-therapy related symptoms and evaluate the need to include an ongoing individualized plan to manage symptoms in clinical practice.
| Reliability
Excellent evidence of reliability was provided using two approaches. 
| CONCLUSION
Our study demonstrated that the Spanish CSS has good validity and excellent internal consistency for assessing cancer-therapy related symptoms. It discriminates between participants receiving chemotherapy treatment and those in post/treatment/survivorship clinics.
Although symptom management is a clinical priority of comprehensive oncology care, the assessment of symptoms in Hispanic adult men and women during cancer treatments has received limited attention. With the worldwide increase in migration of Spanish-speaking families, and that cancer is highly prevalent among the Hispanics population (Centeno-Girona et al., 2013) , nurses need to become familiar with and use valid and reliable symptom assessment instruments to provide culturally competent nursing practice (Sanchez et al., 2016; Trujillo et al., 2016) .
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